28.09 09:02 | dpa-AFX: J&J : DARZALEX FASPRO Quadruplet Regimen Improves MRD Negativity In Newly Diagnosed Multiple Myeloma |
28.09 08:14 | dpa-AFX: J&J : Phase 3 Trial Results Show CARVYKTI Extends Overall Survival In Relapsed Multiple Myeloma |
27.09 22:26 | dpa-AFX: Johnson & Johnson Says Darzalex Regimens Show Meaningful Responses In Patients With Multiple Myeloma |
27.09 14:49 | dpa-AFX: Johnson & Johnson Reports New Data From Phase 1b TRIMM-2 Study |
27.09 14:30 | dpa-AFX: J&J Reports Data From Investigational Phase 1b RedirecTT-1 Study |
27.09 14:10 | dpa-AFX: *J&J : TALVEY AND TECVAYLI SHOW HIGH RESPONSE RATES IN TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA |
27.09 14:07 | dpa-AFX: *JOHNSON & JOHNSON ANNOUNCES PHASE 1B TRIMM-2 RESULTS EVALUATING TALVEY WITH DARZALEX FASPRO |
27.09 09:34 | EU-Zulassung für Stelara-Biosimilar von Formycon und Fresenius Kabi |
21.09 07:21 | dpa-AFX: J&J's Subsidiary Red River Talc Files For Chapter 11 Bankruptcy To Resolve Ovarian Cancer Claims |
20.09 14:04 | dpa-AFX: Janssen-Cilag Reports CHMP Recommendation For Daratumumab |
20.09 13:43 | dpa-AFX: *J&J : DARZALEX QUADRUPLET REGIMEN GETS POSITIVE CHMP OPINION FOR NEWLY DIAGNOSED MYELOMA PATIENTS |
20.09 02:47 | dpa-AFX: FDA Okays J&J's RYBREVANT For Advanced Non-Small Cell Lung Cancer In Combination With Chemotherapy |
16.09 09:33 | dpa-AFX: Johnson & Johnson Reports Promising Interim Data From Phase 2 SunRISe-4 Study |
16.09 08:55 | dpa-AFX: *J&J ANNOUNCES INTERIM DATA FROM PHASE 2 SUNRISE-4 STUDY OF TAR-200 COMBINATION IN MUSCLE-INVASIVE BLADDER CANCER |
15.09 10:15 | dpa-AFX: J&J's TAR-200 Phase 2b SunRISe-1 Study Shows 84% Complete Response In High-Risk Bladder Cancer |
14.09 16:39 | dpa-AFX: J&J Announces Promising Phase 1b/2 Data For Amivantamab Combination In Metastatic Colorectal Cancer |
14.09 09:54 | dpa-AFX: J&J: RYBREVANT + Chemotherapy Shows Strong Benefits And Improved Survival In Phase 3 NSCLC Trial |
13.09 07:20 | dpa-AFX: *HSBC RAISES JOHNSON & JOHNSON PRICE TARGET TO 180 (174) USD - 'BUY' |
13.09 07:20 | dpa-AFX: *HSBC HEBT ZIEL FÜR JOHNSON & JOHNSON AUF 180 (174) USD - 'BUY' |
12.09 15:49 | dpa-AFX: Janssen-Cilag Announces First EMA Submission For Nipocalimab |
|